Short answer
NovoCure Ltd (NVCR) filed its Q2 2026 10-Q quarterly report on Jul 23, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $184M (up 15.6% year over year) with net income of −$16M.
Q2 2026 key financials · XBRL
- Revenue
- $184M
- +15.6% YoY · +5.5% QoQ
- Net income
- −$16M
- +61.0% YoY · +78.0% QoQ
- Operating margin
- -5.8%
- Gross margin
- 77.6%
- EPS (diluted)
- −$0.13
- +63.9% YoY · +79.0% QoQ
Source: XBRL data from the NovoCure Ltd (NVCR) Q2 2026 10-Q on SEC EDGAR. USD.
NovoCure Ltd Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability, margin, segment, cash flow, capital deployment, or outlook figures disclosed
Risk Factors
- No risk factors provided; excerpt contains Items 2–6 and signatures only
- No new or changed risks identifiable from the supplied filing text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other NovoCure Ltd quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.